Raymond James analyst Steven Seedhouse maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Outperform and raises the price target from $4 to $6.
Goldman Sachs Initiates Coverage On Agnico Eagle Mines with Buy Rating, Announces Price Target of C$72
Goldman Sachs analyst Emily Chieng initiates coverage on Agnico Eagle Mines (TSX:AEM) with a Buy rating and announces Price Target of C$72.